Marco's Vapor to Permanently Close in Response to FDA Regulations

Regulations by 2FIRSTS.ai

May.14.2024

Marco's Vapor to Permanently Close in Response to FDA Regulations

Marco's Vapor in Illinois' Cherry Valley will permanently close by July 1, 2024 due to FDA regulations on e-cigarettes.

According to a report by the Associated Press on May 14th, Marco's Vapor, a smoke shop in Cherry Valley, Illinois, announced recently that it will permanently close its doors on July 1, 2024 due to the strict regulations imposed by the U.S. Food and Drug Administration (FDA).

Store owner Marco Altamore states that the strict regulation of e-cigarettes by the FDA has made it impossible for him to continue operating in the United States. Currently, only three e-cigarette manufacturers, including Logic Technology Development LLC, NJOY LLC, and RJ Reynolds Vapor Company, are authorized by the FDA to sell their products in the US.

Alta Moreno revealed that the FDA has rejected millions of other e-cigarette devices and e-liquid applications submitted by the e-cigarette industry, including Marco's Vapor's own Custom Clouds brand. Despite the imminent closure of the store, Moreno continues to advocate for the e-cigarette industry.

He said, "Our goal has always been to help people quit smoking. My staff and team receive calls from customers all day, asking, 'I have been your customer for ten years, where should I go next to buy an e-cigarette?' Because my customers will continue to use e-cigarettes, as it is effective for them."

References:

[1] Marco's Vapor permanently closes after a decade of business

Also Read:

[1] John Verbeten Appointed Compliance Office Director by FDA-CTP in 2024

[2] Senate Urges FDA Enforcement on Unauthorized E-Cigarette Sales Review

[3] FDA and DOJ Seize $700k Worth of Illegal E-Cigarettes

[4] FDA to Host Webinar Celebrating 10th Anniversary of "The Real Cost" Campaign

#North America #United States #Open system e-cigarettes #Regulation #FDA

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency

The U.S. FDA has announced the agency-wide deployment of new agentic AI capabilities, providing all employees with an optional multi-step task automation tool. Building on the broad adoption of its earlier large-language-model system, Elsa, the FDA aims to use this next-generation AI workflow to accelerate product review, regulatory oversight, and internal operations, while maintaining strict human supervision and data security.

Dec.02 by 2FIRSTS.ai

Special Report | Anti-Vaping Campaign in the Baltics Goes Sideways

2Firsts analyzes vaping regulations across the Baltic states. Following Latvia’s flavor ban, tax revenues fell and the black market expanded, while similar measures in Estonia and Lithuania have also failed to deliver results. The region’s anti-vaping policies are now triggering market imbalance and policy reassessment.

Oct.13

FDA Calls on Retailers to Remove Illegal E-Cigarettes from Shelves, Will Send List of Legal Products to 300,000 Stores

FDA launches national retail compliance initiative to combat illegal e-cigarette sales targeting youth, issuing guidance materials to over 300k retailers.

Oct.08 by 2FIRSTS.ai

Australian Federal Police Dismantles WA Illegal Tobacco Network Linked to National Syndicate

Australian Federal Police (AFP) and Western Australia Police seized more than five tonnes of illicit tobacco products in Perth, including over four million cigarettes, about 50,000 vapes, and nearly 900 kilograms of loose-leaf tobacco. Authorities allege the operation, linked to a national organised crime syndicate, aimed to evade around $8 million in Commonwealth excise and taxes.